Chemical Models and Chemotherapy in the Sphingolipidoses

  • Norman S. Radin
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 68)


As I left the previous Sphingolipid Symposium that was held here in 1971, I decided to attempt intervening in glucocerebroside metabolism by synthesizing suitable enzyme inhibitors. It seemed possible to help the victims of Gaucher’s disease, and possibly other sphingolipidoses, by slowing down the synthesis of the sphingolipid that accumulates. When you look at the hydrolase activities reported for the tissues from homozygous individuals suffering from sphingolipidoses, and compare the data with the activities in related, heterozygous individuals, the interesting point emerges: there is really not a great difference in specific activities. Where a sick person might exhibit an activity that is 10% of normal, the apparently healthy relative is getting along fine with an activity that may be 25% of normal. It is apparent that, at least in some organs, many victims of sphingolipidoses are hydrolyzing quite a bit of lipid each day. Their problem seems to be that they are making just a bit too much of the lipid each day and the overload is gradually producing a serious accumulation.


Decanoic Acid Hydroxy Acid Brain Microsome Gauche Patient Ceramide Analog 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Basu, S., Schultz, A. M., Basu. M., and Roseman, S. Enzymatic synthesis of galactocerebroside by a galactosyltransferase from embryonic chicken brain. J. Biol. Chem. 246, 4272 (1971).PubMedGoogle Scholar
  2. 2.
    Bause, E. and Legier, G. Isolation and amino acid sequence of a hexadecapeptide from the active site of α-glucosidase A3 from Aspergillus wentii. Z. Physiol. Chem. 355, 438 (1974).CrossRefGoogle Scholar
  3. 3.
    Brady, R. O., Pentchev, P. G., Gal, A. E., Hibbert, S. R., and Dekaban, A. S. Replacement therapy with purified glucocerebrosidase in Gaucher’s disease. New Engl. J. Med. 291, 989 (1974).PubMedCrossRefGoogle Scholar
  4. 4.
    Brenkert, A. and Radin, N. S. Synthesis of galactosyl ceramide and glucosyl ceramide by rat brain: assay procedures and changes with age. Brain Res. 36, 183 (1972).PubMedCrossRefGoogle Scholar
  5. 5.
    Broad, T. E. and Dawson, R. M. C. Formation of ceramide phosphorylethanolamine from phosphatidylethanolamine in the rumen Protozoon Entodinium caudatum. Biochem. J. 134, 659 (1973).PubMedGoogle Scholar
  6. 6.
    Dawson, G. Glycosphingolipid levels in an unusual neurovisceral storage disease characterized by lactosylceramide galactosyl hydrolase deficiency: lactosylceramidosis. J. Lipid Res. 13, 207 (1972).PubMedGoogle Scholar
  7. 7.
    Dawson, G., Stoolmiller, A. C., and Radin, N. S. Inhibition of g-glucosidase by N-(n-hexyl)-O-glucosyl sphingosine in cell strains of neurological origin. J. Biol. Chem. 249, 4634 (1974).Google Scholar
  8. 8.
    Dawson, G. and Sweeley, C. C. In vivo studies on glycosphingolipid metabolism in porcine blood. J. Biol. Chem. 245, 410 (1970).PubMedGoogle Scholar
  9. 9.
    Diringer, H. and Koch, M. A. Biosynthesis of sphingomyelin. Transfer of phosphoryl choline from phosphatidylcholine to erythro-ceramide in a cell-free system. Z. Physiol. Chem. 354, 1661 (1973).Google Scholar
  10. 10.
    Erickson, J. S. and Radin, N. S. N-Hexyl-O-glucosyl sphingosine, an inhibitor of glucosyl ceramide β-glucosidase. J. Lipid Res. 14, 133 (1973).PubMedGoogle Scholar
  11. 11.
    Hildebrand, J., Stoffyn, P., and Hauser, G. Biosynthesis of lactosylceramide by rat brain preparations and comparison with the formation of ganglioside GM1 and psychosine during development. J. Neurochem. 17, 403 (1970).PubMedCrossRefGoogle Scholar
  12. 12.
    Ho, M. W. and O’Brien, J. S. Gaucher’s disease: deficiency of “acid” β-glucosidase and reconstitution of enzyme activity in vitro. Proc. Nat. Acad. Sci. USA 68, 2810 (1971).PubMedCrossRefGoogle Scholar
  13. 13.
    Ho, M. W., O’Brien, J. S., Radin, N. S., and Erickson, J. S. Glucocerebrosidase: reconstitution of activity from macromolecular components. Biochem. J. 131, 173 (1973).PubMedGoogle Scholar
  14. 14.
    Hoshi, M. and Kishimoto, Y. Synthesis of cerebronic acid from lignoceric acid by rat brain preparation. J. Biol. Chem. 248, 4123 (1973).PubMedGoogle Scholar
  15. 15.
    Huterer, S. and Wherrett, J. R. Enrichment of lysosomes in glycosphingolipid content. Trans. Am. Soc. Neurochem. 5, 68 (1974).Google Scholar
  16. 16.
    Hyun, J. C., Misra, R. S., Greenblatt, D., and Radin, N. S. Synthetic inhibitors of glucocerebroside β-glucosidase. Arch. Biochem. Biophys. 166, 382 (1975).PubMedCrossRefGoogle Scholar
  17. 17.
    Jatzkewitz, H. and Stinshoff, K. An activator of cerebroside sulfatase in human normal liver and in cases of congenital metachromatic leukodystrophy. FEBS Lett. 32, 129 (1973).PubMedCrossRefGoogle Scholar
  18. 18.
    Kampine, J. P., Kanfer, J. N., Gal, A. E., Bradley, R. M., and Brady, R. O. Response of sphingolipid hydrolases in spleen and liver to increased erythrocytorhexis. Biochem. Biophys. Acta 137, 135 (1967).PubMedGoogle Scholar
  19. 19.
    Kuske, T. T. and Rosenberg, A. Quantity and fatty acyl composition of the glycosphingolipids of Gaucher spleen. J. Lab. Clin. Med. 80, 523 (1972).PubMedGoogle Scholar
  20. 20.
    Legier, G. Labeling the active center of β-glucosidases A and B of almond emulsin with [3H]6-bromo-6-deoxy-conduritol B epoxide. Z. Physiol. Chem. 351, 25 (1970).CrossRefGoogle Scholar
  21. 21.
    Li, Y.-T., Mazotta, M. Y., Wan, C.-C., Orth, R., and Li, S.-C. Hydrolysis of Tay-Sachs ganglioside by 3-hexosaminidase A of human liver and urine. J. Biol. Chem. 248, 7512 (1973).PubMedGoogle Scholar
  22. 22.
    Makita, A., Suzuki, C., and Yosizawa, Z. Glycolipids isolated from the spleen of Gaucher’s disease. J. Exptl. Med. (Tohoku) 88, 277 (1966).CrossRefGoogle Scholar
  23. 23.
    Morell, P. and Radin, N. S. Specificity in ceramide biosynthesis from long chain bases and various fatty acyl Coenzyme A’s by brain microsomes. J. Biol. Chem. 245, 342 (1970).PubMedGoogle Scholar
  24. 24.
    Morell, P. and Radin, N. S. Synthesis of cerebroside by brain from uridine diphosphate galactose and ceramide containing hydroxy fatty acid. Biochem. 8, 506 (1969).CrossRefGoogle Scholar
  25. 25.
    Ong, D. E. and Brady, R. N. In vivo studies on the introduction of the 4-t double bond on the sphingenine-3-moiety of rat brain ceramides. J. Biol. Chem. 248, 3884 (1973).PubMedGoogle Scholar
  26. 26.
    Philippart, M. Glycolipid, mucopolysaccharide and carbohydrate distribution in tissues, plasma and urine from glycolipidoses and other disorders. In Advances in Experimental Medicine and Biology, V. Zambotti, G. Tallamanti, and M. Arrigone, eds. Plenum Press, New York, vol. 25, p. 231 (1972).Google Scholar
  27. 27.
    Radin, N. S., Warren, K. R., Arora, R. C., Hyun, J. C., and Misra, R. S. In Modification of Lipid Metabolism, E. G. Perkins and L. A. Witting, eds., Academic Press, New York, 1975, 87–104.Google Scholar
  28. 28.
    Shah, S. N. Glycosyl transferases of microsomal fractions from brain: synthesis of glucosyl ceramide and galactosyl ceramide during development and the distribution of glucose and galactose transferase in white and grey matter. J. Neurochem. 18, 395 (1971).PubMedCrossRefGoogle Scholar
  29. 29.
    Trams, E. G. and Brady, R. O. J. Clin. Invest. 39, 1546 (1960).CrossRefGoogle Scholar
  30. 30.
    Ullman, M. D. and Radin, N. S. Enzymatic formation of hydroxy ceramides and comparison with enzymes forming nonhydroxy ceramides. Arch. Biochem. Biophys. 152, 767 (1972).PubMedCrossRefGoogle Scholar
  31. 31.
    Ullman, M. D. and Radin, N. S. The enzymatic formation of sphingomyelin from ceramide and lecithin in mouse liver. J. Biol. Chem. 249, 1506 (1974).PubMedGoogle Scholar
  32. 32.
    Warren, K. R., Misra, R. S., Arora, R. C., and Radin, N. S. Glycosyltransferases of rat brain that make cerebrosides: substrate specificity, inhibitors, and abnormal products. J. Neurochem. in press.Google Scholar
  33. 33.
    Warren, K. R., Schafer, I. A., Sullivan, J. C., Petrelli, M., and Radin, N. S. The effects of N-hexyl-O-glucosyl sphingosine on normal cultured human fibroblasts: a chemical model for Gaucher’s disease. J. Lipid Res. in press.Google Scholar
  34. 34.
    Wenger, D. A. Studies on galactosyl ceramide and lactosyl ceramide β-galactosidase. Chem. Phys. Lipids 13, 327 (1974).PubMedCrossRefGoogle Scholar
  35. 35.
    Tanaka, H. and Suzuki, K. Lactosylceramide β-galactosidase in human sphingolipidoses. J. Biol. Chem. 250, 2324 (1975).PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1976

Authors and Affiliations

  • Norman S. Radin
    • 1
  1. 1.Mental Health Research Institute and Department of Biological ChemistryUniversity of MichiganAnn ArborUSA

Personalised recommendations